Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501759 · ClinicalTrials.gov registry record · NA
Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer
A NA study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02501759: Clinical Trial NA study, sponsored by OHSU Knight Cancer Institute.
NCT02501759 is a NA study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02501759, a NA study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy. Transrectal MRI-guided biopsy uses a thin needle inserted through the rectum into the prostate and takes a sample of tissue, guided by MRI. MRI uses magnets to take pictures of the prostate and may be able to identify cancer. Transrectal MRI-guided biopsy may be more accurate and cause patients less pain than standard ultrasound-guided biopsy. It is not yet known whether transrectal MRI-guided biopsy is more effective than ultrasound-guided biopsy in identifying prostate cancer.
Primary Outcome
The proportion of MRI-guided biopsies that demonstrate a higher Gleason score than contemporaneous TRUS guided biopsy for all patients diagnosed of prostate cancer based on the reference standard will be estimated. McNemar's test will be used to assess whether the MRI-guided biopsies are more likely to yield a higher Gleason score compared with TRUS guided biopsy. Simple logistic regression model will be used to assess the association between the higher Gleason score and patient characteristics
Interventions
- PROCEDURE Multiparametric Magnetic Resonance Imaging
- PROCEDURE Ultrasound-Guided Prostate Biopsy
- PROCEDURE 3 Tesla Magnetic Resonance Imaging
- RADIATION Gadodiamide
- PROCEDURE Transrectal Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-02-10 |
| Phase | NA |
Why NCT02501759 stopped before completion
NCT02501759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Multiparametric Magnetic Resonance Imaging is the first listed.
NCT02501759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02501759 about?
NCT02501759 is a clinical study titled "Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer". This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy. Transrectal MRI-guided biopsy uses a thin needle inserted through the r...
What is the current status of trial NCT02501759?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2015-05. Estimated completion is 2017-02-10.
What interventions are being tested in trial NCT02501759?
The interventions under investigation include: Multiparametric Magnetic Resonance Imaging (PROCEDURE), Ultrasound-Guided Prostate Biopsy (PROCEDURE), 3 Tesla Magnetic Resonance Imaging (PROCEDURE), Gadodiamide (RADIATION), Transrectal Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02501759?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02501759's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia